FDA Shortens Tarlatamab Monitoring, Widens Access to SCLC Care

A regulatory change that trims the required monitoring window for the first 2 doses of tarlatamab-dlle (Imdelltra; Amgen) from 22 to 24 hours down to just 6 to 8 hours could make it substantially easier for community oncology practices to administer the therapy, according to the FDA approval announced by Amgen.¹ The agency's update to the drug's prescribing information also adds a follow-up vital-signs check the day after each of those first 2 infusions but otherwise leaves the monitoring and supportive care schedule for later doses unchanged.

Tarlatamab is a first-in-class bispecific T-cell engager indicated for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The drug carries a boxed warning for cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell–associated neurotoxicity syndrome (ICANS), which is why patients have historically needed to be monitored in a health care setting for nearly a full day after their initial doses.

Why the Monitoring Change Matters for Access

An estimated 80% to 85% of patients with cancer in the US receive care in community oncology settings rather than academic medical centers.² A 22- to 24-hour monitoring requirement is difficult to accommodate outside a hospital-based infusion unit, and the burden appears to fall hardest on patients in rural or underserved areas who may already face long drives to reach a cancer center.

"People being treated for small cell lung cancer are already navigating an aggressive and difficult-to-treat disease, and the time required to receive and monitor treatment can add to that burden for both patients and care centers," Jay Bradner, MD, executive vice president of research and development, artificial intelligence, and data at Amgen, said in a statement.¹ Bradner said the shorter monitoring window "may help address practical barriers associated with administering Imdelltra and enable more patients to receive care closer to home."

David M. Waterhouse, MD, MPH, a medical oncologist at Oncology Hematology Care in Cincinnati, Ohio, echoed that point, noting that patients with ES-SCLC “are often very sick, and traveling long distances or spending extended time in a healthcare setting can be difficult for them and their families.” Community oncology practices may be uniquely positioned to help address similar barriers facing rural patients with cancer, including transportation and logistical burdens. As Tennessee Oncology's Stephen Schleicher, MD, MBA, put it, "our clinics are in these areas, bringing access to rural populations of patients."³

What Does the New Monitoring Schedule Look Like?

Under the updated label, patients now need only 6 to 8 hours of monitoring from the start of infusion following the first 2 doses (cycle 1, day 1, and cycle 1, day 8), plus a follow-up assessment, including vital signs, the day after each. Patients are still advised to remain within an hour of an appropriate health care setting for a total of 48 hours after those doses, accompanied by a caregiver. The rest of the schedule holds steady: 6 to 8 hours of monitoring after the third dose and through cycle 2, dropping to 3 to 4 hours for cycles 3 and 4, and 2 hours for cycle 5 and beyond.

The change comes as Amgen continues to build out evidence for tarlatamab earlier in the treatment course. The company recently reported topline overall survival data from the phase 3 DeLLphi-305 trial testing tarlatamab plus durvalumab (Imfinzi; AstraZeneca) as first-line maintenance therapy in ES-SCLC.⁴ In that trial, patients who had not progressed on induction chemotherapy plus durvalumab were monitored for just 1 to 2 hours after their first 2 tarlatamab infusions in some regions and 6 to 8 hours in others, including Europe, which is a lighter protocol than what had been standard in the US until this approval.⁴

Implications for Site-of-Care Capacity and Cost

A shorter monitoring requirement lowers the resource intensity of administering a bispecific T-cell engager therapy outside a hospital setting, potentially expanding the number of sites capable of offering tarlatamab and reducing costs tied to extended observation stays. It may also ease scheduling and staffing pressure on community infusion centers that have had to treat the drug's original monitoring window as a near-inpatient commitment.

The underlying safety profile has not changed. In the pooled safety population supporting tarlatamab’s approval, CRS occurred in 57% of patients and neurologic toxicity in 65%, with the majority of CRS events following those first 2 doses that are now subject to shorter observation.⁵ Community practices adopting the new protocol will still need clear pathways for recognizing and managing CRS and ICANS after patients are discharged, since counseling patients and caregivers on warning signs remains part of the updated administration requirements.

"In community oncology, we care for patients where they live, and for people living with small cell lung cancer, that matters," said Waterhouse.¹

References

1. FDA approves reduced monitoring time for first two doses of IMDELLTRA. Amgen. News release. September 14, 2026. Accessed September 14, 2026. https://www.amgen.com/newsroom/press-releases/2026/09/fda-approves-reduced-monitoring-time-for-first-two-doses-of-imdelltra
2. Ruemu Ejedafeta Birhiray, Maya Nicole Birhiray. Clinical research in the community. Hematology Am Soc Hematol Educ Program 2023; 2023 (1): 324–331. doi:10.1182/hematology.2023000432
3. Shaw ML. Dr Stephen Schleicher: rural patient care access is a top priority for community oncology. AJMC. May 4, 2023. Accessed September 14, 2026. https://www.ajmc.com/view/dr-stephen-schleicher-rural-patient-care-access-is-a-top-priority-for-community-oncology
4. Steinzor P. Tarlatamab-dlle plus durvalumab improves survival in first-line ES-SCLC. AJMC. September 8, 2026. Accessed September 14, 2026. https://www.ajmc.com/view/tarlatamab-dlle-plus-durvalumab-improves-survival-in-first-line-es-sclc
5. IMDELLTRA (tarlatamab-dlle) prescribing information. Amgen. Accessed September 14, 2026. https://www.pi.amgen.com/united_states/Imdelltra/imdelltra_fpi.pdf